Stock Rating Upgrade
The Value Trend Rating for Biomarin Pharmaceutical Inc (NASDAQ: BMRN) improved in recent days from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
On 9/20/24, Biomarin Pharmaceutical Inc (NASDAQ: BMRN) stock declined modestly by -1.0%, closing at $70.69. Moreover, unusually high trading volume at 183% of normal accompanied the decline. Relative to the market the stock has been weak over the last nine months and has declined -16.2% during the last week.
Current PriceTarget Research Rating
BMRN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Biomarin Pharmaceutical has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Biomarin Pharmaceutical has a neutral Appreciation Score of 49 and a neutral Power Rating of 45, producing the Low Neutral Value Trend Rating.
Be the first to comment